Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer

Autor: Margherita Ratti, Jens C. Hahne, Michele Ghidini, Milko Mirchev, Nicola Valeri, Andrea Lampis, Ali Fuat Okuducu
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
medicine.medical_specialty
Gastrointestinal tumors
lcsh:QH426-470
pancreatic cancer
Review
mismatch repair system
Cancer Vaccines
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Immune system
Pancreatectomy
Internal medicine
Pancreatic cancer
Antineoplastic Combined Chemotherapy Protocols
Genetics
Medicine
Humans
immune-based therapy
Precision Medicine
Immune Checkpoint Inhibitors
Genetics (clinical)
Clinical Trials as Topic
business.industry
Patient Selection
Microsatellite instability
Cancer
Treatment options
medicine.disease
Prognosis
Colorectal Neoplasms
Hereditary Nonpolyposis

Lynch syndrome
digestive system diseases
Pancreatic Neoplasms
Survival Rate
lcsh:Genetics
030104 developmental biology
Chemotherapy
Adjuvant

030220 oncology & carcinogenesis
Mutation
Microsatellite Instability
Immunotherapy
Neoplasm Recurrence
Local

business
Aggressive malignancies
Zdroj: Genes
Genes, Vol 12, Iss 33, p 33 (2021)
ISSN: 2073-4425
Popis: Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus resulting in high morbidity and mortality. Among all cancers, with a five-year survival rates of only 2–9%, pancreatic cancer holds the worst prognostic outcome for patients. To improve the overall survival, an earlier diagnosis and stratification of cancer patients for personalized treatment options are urgent needs. A minority of pancreatic cancers belong to the spectrum of Lynch syndrome-associated cancers and are characterized by microsatellite instability (MSI). MSI is a consequence of defective mismatch repair protein functions and it has been well characterized in other gastrointestinal tumors such as colorectal and gastric cancer. In the latter, high levels of MSI are linked to a better prognosis and to an increased benefit to immune-based therapies. Therefore, the same therapies could offer an opportunity of treatment for pancreatic cancer patients with MSI. In this review, we summarize the current knowledge about immune-based therapies and MSI in pancreatic cancer.
Databáze: OpenAIRE